H-CYTE is a medical biosciences company. H-CYTE’s mission is to become a leader in next-generation, cellular therapeutics for the treatment of chronic health conditions, with the ultimate goal of improving patient lives. For more information about H-CYTE, please visit www.HCYTE.com.
Company profile
Ticker
IVRN
Exchange
Website
CEO
William E. Horne
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
H-CYTE, INC., Medovex Corp., SpineZ
SEC CIK
Corporate docs
Subsidiaries
Debride, Inc. • STML Merger Sub, Inc. ...
IVRN stock data
Latest filings (excl ownership)
NT 10-K
Notice of late annual filing
2 Apr 24
8-K
Departure of Directors or Certain Officers
1 Apr 24
8-K
Innoveren Scientific Announces 510(k) Submission for SkinDiscTM Lite
6 Mar 24
8-K
Entry into a Material Definitive Agreement
28 Feb 24
8-K
Regulation FD Disclosure
21 Dec 23
10-Q
2023 Q3
Quarterly report
15 Nov 23
NT 10-Q
Notice of late quarterly filing
15 Nov 23
10-Q
2023 Q2
Quarterly report
14 Nov 23
8-K
Entry into a Material Definitive Agreement
3 Oct 23
NT 10-Q
Notice of late quarterly filing
15 Aug 23
Latest ownership filings
SC 13G/A
Lynch Frederick J
14 Feb 24
SC 13D/A
FWHC HOLDINGS, LLC
6 Feb 24
4
TODD R WAGNER
18 Jan 24
4
J REX FARRIOR III
18 Jan 24
SC 13G/A
Lynch Frederick J
10 Feb 23
4
Frederick J Lynch
23 Mar 22
4
J REX FARRIOR III
25 Feb 22
4
TODD R WAGNER
25 Feb 22
SC 13D/A
FWHC HOLDINGS, LLC
25 Feb 22
3
Frederick J Lynch
17 Feb 22
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 544.00 k | 544.00 k | 544.00 k | 544.00 k | 544.00 k | 544.00 k |
Cash burn (monthly) | (no burn) | (no burn) | 140.42 k | 240.13 k | 108.66 k | 76.51 k |
Cash used (since last report) | n/a | n/a | 965.54 k | 1.65 mm | 747.13 k | 526.07 k |
Cash remaining | n/a | n/a | -421.54 k | -1.11 mm | -203.13 k | 17.93 k |
Runway (months of cash) | n/a | n/a | -3.0 | -4.6 | -1.9 | 0.2 |
Institutional ownership, Q4 2021
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
16 Jan 24 | J Rex Farrior Iii | COMMON STOCK | Conversion | Acquire C | Yes | No | 0 | 13,168 | 0.00 | 29,381 |
16 Jan 24 | J Rex Farrior Iii | SERIES A PREFERRED STOCK COMMON STOCK | Conversion | Dispose C | Yes | No | 0 | 13,168,000 | 0.00 | 1,464,000 |
16 Jan 24 | Todd R Wagner | COMMON STOCK | Conversion | Acquire C | Yes | No | 0 | 303,107 | 0.00 | 344,716 |
16 Jan 24 | Todd R Wagner | SERIES A PREFERRED STOCK COMMON STOCK | Conversion | Dispose C | Yes | No | 0 | 303,107,000 | 0.00 | 33,682,000 |